Rivastigmine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Rivastigmine: Glaucoma
One-Sentence Summary
Rivastigmine is a cholinesterase inhibitor originally used to treat Alzheimer’s disease. The TxGNN model predicts it may be effective for glaucoma, but the support is currently limited to 0 registered clinical trials and 3 publications (one animal study and two reviews), so this remains an early-stage research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 0.9927 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Rivastigmine inhibits the enzymes that break down acetylcholine. Detailed mechanism of action data are not available in the data compiled for this report. Based on known information, rivastigmine is a cholinesterase inhibitor whose efficacy in Alzheimer’s disease is established, and mechanistically it may be applicable to glaucoma.
Cholinergic stimulation at the ciliary muscle and trabecular meshwork may increase aqueous outflow and lower intraocular pressure, as seen with cholinergic agents such as pilocarpine. A 2000 rabbit study reported that topical rivastigmine lowered intraocular pressure in normotensive animals.
This is preclinical evidence only. No human trials are listed. Ocular safety, local tolerability and a topical formulation are untested, and the only Australian product is a transdermal patch.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Preclinical (rabbit) | J Ocul Pharmacol Ther | Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowered intraocular pressure in rabbits |
| 39130374 | 2024 | Review | Front Mol Biosci | Cholinergic agents for intraocular pressure reduction. Systemic cholinergic adverse effects limit clinical use of existing agents |
| 27967267 | 2017 | Review (patents) | Expert Opin Ther Pat | Mild acetylcholinesterase inhibition has therapeutic relevance in Alzheimer’s disease, myasthenia gravis and glaucoma |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10538P | Exelon Patch 15 | Transdermal patch 27 mg | Not stated in the data compiled |
Safety Considerations
- Disease-level contraindication signals (knowledge graph, not label text): epilepsy, asthma (including intrinsic and allergic), chronic obstructive pulmonary disease, active peptic ulcer disease, urinary tract obstruction, diarrhoeal disease, anorexia nervosa, Parkinson disease and parkinsonian disorders, basal ganglia disease, focal hand dystonia, blepharospasm, sudden cardiac arrest, heart conduction disease, sick sinus syndrome (including the familial form) and atrioventricular block.
- Drug interactions: 100 interactions were identified, with the 20 below listed in the data compiled.
- Major: bupropion.
- Moderate: famotidine, ranitidine, cimetidine, hyoscyamine, atropine, glycopyrronium, clidinium, dicyclomine, trospium, mepenzolate, loperamide, metronidazole, clarithromycin, levofloxacin, dolasetron, palonosetron, picosulfuric acid, polyethylene glycol (3350 with electrolytes) and sodium sulfate.
- Movement disorders: A 2025 systematic review and a case report of dyskinesia on the rivastigmine patch indicate that acetylcholinesterase inhibitors can induce or worsen movement disorders.
Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The glaucoma prediction has a high model score and a plausible cholinergic mechanism, but the only supporting data are one rabbit study and two reviews. There are no human trials, and the only Australian product is a transdermal patch, not an ocular formulation.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA)
- Product Information warnings and contraindications for the Australian product
- Preclinical safety and tolerability studies of a topical ocular formulation
- Confirmation of the efficacy signal in additional animal models, followed by early-phase human studies
- A review of the contraindication signals above (for example bradycardia, asthma and COPD) for systemic exposure, if relevant
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.